| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Absorption, metabolism, and excretion of inavolisib (GDC-0077), a PI3KA inhibitor in humans
|
Cho, Sungjoon
|
|
|
55 |
S |
p.
|
artikel
|
| 2 |
Abstract withdrawn
|
|
|
|
55 |
S |
p.
|
artikel
|
| 3 |
Abstract withdrawn
|
|
|
|
55 |
S |
p.
|
artikel
|
| 4 |
Acetaminophen-induced liver injury and the microbiome
|
Jeong, Young
|
|
|
55 |
S |
p.
|
artikel
|
| 5 |
ADME considerations from FIH to drug approval
|
Sanchez, Rosa
|
|
|
55 |
S |
p.
|
artikel
|
| 6 |
ADME: 14C-RLY-4008 following oral administration to rats
|
Barton, Eleanor
|
|
|
55 |
S |
p.
|
artikel
|
| 7 |
A live cell high content imaging assay for monitoring large molecule uptake into aproximate proximal tubule epithelial cells via megalin and cubilin
|
Lowe, Jonathon
|
|
|
55 |
S |
p.
|
artikel
|
| 8 |
Alternatives to rifampin: A perspective on conducting clinical drug interaction studies
|
Bolleddula, Jayaprakasam
|
|
|
55 |
S |
p.
|
artikel
|
| 9 |
An approach using a gamma-distributed delay model to evaluate the anticancer effect of doxorubicin-encapsulated polymeric micelles by predictive pharmacokinetic-pharmacodynamic modeling
|
Yamashita, Shugo
|
|
|
55 |
S |
p.
|
artikel
|
| 10 |
Anchored intratumoral cytokine immunotherapy
|
Wittrup, Dane
|
|
|
55 |
S |
p.
|
artikel
|
| 11 |
A new trapping method to quantitatively assess the formation of reactive metabolites from drugs which cause agranulocytosis
|
Kawachi, Tomoyuki
|
|
|
55 |
S |
p.
|
artikel
|
| 12 |
An in vitro microphysiological model of subcutaneous delivery
|
Kamm, Roger
|
|
|
55 |
S |
p.
|
artikel
|
| 13 |
A novel 3D imaging pipeline for analyzing efficacy of compounds on amyloid-beta plaque dynamics in preclinical alzheimer’s disease animal models
|
Ferron, Gianna
|
|
|
55 |
S |
p.
|
artikel
|
| 14 |
An overview of CDE technical guideline for nonclinical study of ADCS: importance and strategy of studying release of payload-containing components from ADC and their further metabolism
|
Tang, Chongzhuang
|
|
|
55 |
S |
p.
|
artikel
|
| 15 |
An overview of selected topics in the clinical pharmacology and translation of in vivo CRISPR-based therapies
|
Stroh, Mark
|
|
|
55 |
S |
p.
|
artikel
|
| 16 |
Anti-TNF GRM ADCs: PK/PD considerations to inform clinical development
|
D’Cunha, Ronilda
|
|
|
55 |
S |
p.
|
artikel
|
| 17 |
Approaches to predict human PK profiles for compounds undergoing transporter mediated clearance in early drug development: From dedrick plot to PBPK modeling
|
Liang, Xiaomin
|
|
|
55 |
S |
p.
|
artikel
|
| 18 |
Approach to de-risk structural alerts in compound progression
|
Rotter, Charles
|
|
|
55 |
S |
p.
|
artikel
|
| 19 |
A practical approach for measuring acyl glucuronide migration half life
|
Tan, Ying
|
|
|
55 |
S |
p.
|
artikel
|
| 20 |
Assessing complex drug-drug interactions using the truvivotm hepatocyte model
|
Whitcher-Johnstone, Andrea
|
|
|
55 |
S |
p.
|
artikel
|
| 21 |
Assessing victim drug-drug interaction – Reaction phenotyping of CYP and non-CYP
|
Di, Li
|
|
|
55 |
S |
p.
|
artikel
|
| 22 |
Assessment of covalent binding body burden in Hmrel human hepatocyte co-culture model for metabollically low turnover compounds
|
Shang, Jackie
|
|
|
55 |
S |
p.
|
artikel
|
| 23 |
Assessment of the clinical pharmacokinetic interaction potential mediated So-Cheong-Ryong-Tang on a cocktail of anti-inflammatory and anti-biotic drugs, established by physiologically based pharmacokinetic modelings
|
Kim, Da Hyun
|
|
|
55 |
S |
p.
|
artikel
|
| 24 |
A successful preclinical toxicology package
|
Theodore, Shaji
|
|
|
55 |
S |
p.
|
artikel
|
| 25 |
A synthetic G protein-coupled receptor 40 agonist GW9508 mitigates airway inflammation and mucus secretion in allergic asthma
|
Yimnual, Chantapol
|
|
|
55 |
S |
p.
|
artikel
|
| 26 |
Author Index
|
|
|
|
55 |
S |
p.
|
artikel
|
| 27 |
Automated workflow to study microsomal clearance and analysis of metabolites using collision-induced dissociation and electron-activated dissociation MS/MS data
|
Nandita, Eshani
|
|
|
55 |
S |
p.
|
artikel
|
| 28 |
A workflow for oligonucleotide metabolite identification studies
|
Pei, Ruisong
|
|
|
55 |
S |
p.
|
artikel
|
| 29 |
Basic tenets for the ADME of protein therapeutics
|
Shah, Dhaval
|
|
|
55 |
S |
p.
|
artikel
|
| 30 |
Beyond non-human primates: Transgenics and PBPK models for predicting the human PK of protein therapeutics
|
Betts, Alison
|
|
|
55 |
S |
p.
|
artikel
|
| 31 |
Biosynthesis of the BI 894416 metabolite M398(2) using microbial enzymes
|
Auclair, Adam
|
|
|
55 |
S |
p.
|
artikel
|
| 32 |
Biotransformation of protein degraders bavdegalutamide and XL01126 in permeabilized cryopreserved human hepatocytes
|
Ma, Bin
|
|
|
55 |
S |
p.
|
artikel
|
| 33 |
Bringing totality-of-evidence into PBPK predictions: fraction metabolised by aldehyde oxidase
|
Izat, Nihan
|
|
|
55 |
S |
p.
|
artikel
|
| 34 |
Can LS180 cells predict metabolism and drug-drug interaction potential of UGT2B17 substrates?
|
Bachhav, Namrata
|
|
|
55 |
S |
p.
|
artikel
|
| 35 |
Cannabinoid-induced drug-drug interactions with hydromorphone.
|
Coates, Shelby
|
|
|
55 |
S |
p.
|
artikel
|
| 36 |
Can prostaglandins be used as biomarkers for atypical antipsychotic mediated immune system dyregulation in zebra fish?
|
Barlow, Deborah
|
|
|
55 |
S |
p.
|
artikel
|
| 37 |
Catabolites identification and quantification of antisense oligonucleotides by liquid chromatography - high resolution mass spectrometry (LC-HRMS)
|
Zhang, Xin
|
|
|
55 |
S |
p.
|
artikel
|
| 38 |
Challenges and opportunities of modeling and simulation in pediatrics: Adults are just big children
|
Leeder, J. Steven
|
|
|
55 |
S |
p.
|
artikel
|
| 39 |
Challenges associated with the biomarker-informed PBPK modeling of renal transporter-mediated drug interactions
|
Kimoto, Emi
|
|
|
55 |
S |
p.
|
artikel
|
| 40 |
Challenges in PBPK modeling of phenolic drugs extensively metabolized by intestinal phase II enzyme
|
Singh, Rashim
|
|
|
55 |
S |
p.
|
artikel
|
| 41 |
Characterization of a novel human hepatocyte model, truvivo™ for the projection of clinical induction of drug metabolizing enzymes
|
Slavsky, Marina
|
|
|
55 |
S |
p.
|
artikel
|
| 42 |
Characterization of 14 pharmaceutical excipients in the CACO-2 permeability assay
|
Xiong, Tao
|
|
|
55 |
S |
p.
|
artikel
|
| 43 |
Clinical DDI trial design and impact on product labels
|
Akhlaghi, Fatemeh
|
|
|
55 |
S |
p.
|
artikel
|
| 44 |
Clinical studies on pharmacogenomics and DDIS involving drug transporters
|
Yang, Xinning
|
|
|
55 |
S |
p.
|
artikel
|
| 45 |
Clinical studies on pharmacogenomics and DDIS involving drug transporters
|
Morse, Bridget
|
|
|
55 |
S |
p.
|
artikel
|
| 46 |
Clotrimazole is a potent and selective UGT2B4 chemical inhibitor
|
Chandrashekhar, Megha
|
|
|
55 |
S |
p.
|
artikel
|
| 47 |
Comparative analysis of microcystin toxicity in 2D and 3D cultured primary human hepatocytes
|
Richardson, Vicki
|
|
|
55 |
S |
p.
|
artikel
|
| 48 |
Comparison of clearance and metabolic pathways in suspension hepatocytes and hepatopac cultures
|
Liu, Joyce
|
|
|
55 |
S |
p.
|
artikel
|
| 49 |
Comparison on metabolic fate of dendrobium polysaccharides in gut microbiota fermentation process between healty and diabetic status
|
Zuo, Zhong
|
|
|
55 |
S |
p.
|
artikel
|
| 50 |
14C-radiolabeled human ADME: a review of clinical microtracer mass balance data
|
Croft, Marie
|
|
|
55 |
S |
p.
|
artikel
|
| 51 |
CYP46A1 inhibition and activation: an in vitro high throughput screening assay to assess possible drug interactions using FDA approved chemical library
|
Adusumalli, Sravani
|
|
|
55 |
S |
p.
|
artikel
|
| 52 |
CYP and UGT inhibition to assess perpetrator drug-drug interaction potential
|
Zientek, Michael
|
|
|
55 |
S |
p.
|
artikel
|
| 53 |
CYP2D in the brain alters the development of analgesic tolerance and behavioral sensitization to repeated oral oxycodone
|
Richards, Janielle
|
|
|
55 |
S |
p.
|
artikel
|
| 54 |
Cytokine mediated modulation of drug metabolizing enzymes observed at physiologically relevant levels in truvivo hepatocyte model
|
Aluri, Krishna
|
|
|
55 |
S |
p.
|
artikel
|
| 55 |
Deciphering the cell and zonal distribution of drug metabolizing enzymes and transporters in humans by single cell transcriptomics
|
Lim, Joe
|
|
|
55 |
S |
p.
|
artikel
|
| 56 |
De-risking idiosyncratic adverse drug reactions and toxicities in drug discovery utilizing a qualitative in-vitro high-throughput reactive metabolite trapping method
|
Roychowdhury, Shantanu
|
|
|
55 |
S |
p.
|
artikel
|
| 57 |
Designing novel RNA medicines for the brain
|
Alterman, Julia
|
|
|
55 |
S |
p.
|
artikel
|
| 58 |
Determination of metabolic pathways of phosphatidylcholine and lysophosphatidylcholine using a stable isotope tracer in hepatocarcinoma cell lines
|
Choi, Jeong Eun
|
|
|
55 |
S |
p.
|
artikel
|
| 59 |
Determination of pharmacokinetics of acetaminophen and assessment of impact to animal health following serial liver biopsies in cynomologus monkeys
|
Favara, Sarah
|
|
|
55 |
S |
p.
|
artikel
|
| 60 |
Development and validation of PAMPA-BBB QSAR model to determine brain penetration of novel drug candidates
|
Shah, Pranav
|
|
|
55 |
S |
p.
|
artikel
|
| 61 |
Development of a high throughput screen for cytochrome P450-ligand binding assays
|
Frydendall, Ellie
|
|
|
55 |
S |
p.
|
artikel
|
| 62 |
Development of a HRMS-MS method for measuring plasma 4Β-hydroxycholesterol, an endogenous biomarker of CYP3A activity, in monkeys treated with CYP3A modulators
|
King-Ahmad, Amanda
|
|
|
55 |
S |
p.
|
artikel
|
| 63 |
Development of an in vitro metabolism approach of acrylamide covalent drugs for predicting metabolism and disposition in human
|
Li, Ruixing
|
|
|
55 |
S |
p.
|
artikel
|
| 64 |
Development of a novel in silico classification model to assess reactive metabolite formation in cysteine trapping assay and investigation of important substructures
|
Umemori, Yuki
|
|
|
55 |
S |
p.
|
artikel
|
| 65 |
Development of a simple, fast inhibition assay for rat CYP3A enzymes
|
Voice, Michael
|
|
|
55 |
S |
p.
|
artikel
|
| 66 |
Development of physiologically-based pharmacokinetic models to predict food effects and co-administration of proton pump inhibitors on the pharmacokinetics of sonidegib and vismodegib
|
Kim, Duk Yeon
|
|
|
55 |
S |
p.
|
artikel
|
| 67 |
Development of plasma stability assay for oligonucleotides
|
Wang, Xiangling
|
|
|
55 |
S |
p.
|
artikel
|
| 68 |
Development of quantitative translational model of neutropenia using nonclinical animal data and physiological parameters
|
Wakayama, Naomi
|
|
|
55 |
S |
p.
|
artikel
|
| 69 |
Development of serotonin release assay with cultured enterochromaffin cells for the risk assessment of emesis induced by tyrosine kinase inhibitors
|
Hashimoto, Yoshiki
|
|
|
55 |
S |
p.
|
artikel
|
| 70 |
Dose selection in phase I trials: a review of development programs from approved drugs to investigate intrinsic and extrinsic factors on pharmacokinetics and safety.
|
Kaspera, Rudiger
|
|
|
55 |
S |
p.
|
artikel
|
| 71 |
Drug induced organ toxicity: Transporter roles and derisking approaches
|
Sprowl, Jason
|
|
|
55 |
S |
p.
|
artikel
|
| 72 |
Drug metabolism: A half-century plus of progress, continued needs, and new opportunities
|
Guengerich, F. Peter
|
|
|
55 |
S |
p.
|
artikel
|
| 73 |
Drug metabolism by the human gut microbiome
|
Eng, Heather
|
|
|
55 |
S |
p.
|
artikel
|
| 74 |
Dynamic free fraction: concept, methodology and impact on hepatic clearance prediction using the well-stirred model
|
Ma, Li
|
|
|
55 |
S |
p.
|
artikel
|
| 75 |
Effect of linker-payload design on the PK of ADCS
|
Lyon, Robert
|
|
|
55 |
S |
p.
|
artikel
|
| 76 |
Effect of pregnancy-related hormones on mRNA expression of hepatic drug transporters and enzymes
|
Richard de Lima Benzi, Jhohann
|
|
|
55 |
S |
p.
|
artikel
|
| 77 |
Effect of substrate concentration on reactive metabolite assessment in drug discovery research
|
Ozawa, Makoto
|
|
|
55 |
S |
p.
|
artikel
|
| 78 |
Effects of genetic polymorphisms of canine CYP2D15 on in vitro hepatic metabolism and in vivo pharmacokinetics of celecoxib, and the strategy for the accurate prediction of human pharmacokinetics
|
Yanai, Miyuu
|
|
|
55 |
S |
p.
|
artikel
|
| 79 |
Elacridar leads to a much more pronounced boost in dog absorption than expected based on available non-clinical and clinical observations
|
Ramsden, Diane
|
|
|
55 |
S |
p.
|
artikel
|
| 80 |
Elucidate the metabolism of lipidated serotonin and selected drugs by cytochrome P450 2U1 (CYP2U1) in nanodiscs
|
Tang, Yi-Chien
|
|
|
55 |
S |
p.
|
artikel
|
| 81 |
Encequidar is a gut-restricted P-GP specific inhibitor that boosts oral bioavailability and inhibits intestinal secretion in rats and dogs.
|
Subramanian, Murali
|
|
|
55 |
S |
p.
|
artikel
|
| 82 |
Endogenous metabolites change associated with pioglitazone administration in healthy male subjects
|
Kang, Jihyun
|
|
|
55 |
S |
p.
|
artikel
|
| 83 |
Endosomal escape for intracellular delivery of RNA therapeutics: current and future strategies
|
MacLauchlin, Chris
|
|
|
55 |
S |
p.
|
artikel
|
| 84 |
Engineering proteins to achieve desired ADME characteristics
|
Chapporo-Riggers, Javier
|
|
|
55 |
S |
p.
|
artikel
|
| 85 |
Enriching metabolite fractions for assessment of AHR activation potential: a proof of concept study
|
Erdemir, Ili
|
|
|
55 |
S |
p.
|
artikel
|
| 86 |
Enzyme induction fundamentals, assays, data interpretation and in vivo translation
|
Ramsden, Diane
|
|
|
55 |
S |
p.
|
artikel
|
| 87 |
Establishment and characterization of an in vitro model for NTCP substrate and inhibition assessment
|
Xiong, Tao
|
|
|
55 |
S |
p.
|
artikel
|
| 88 |
Establishment of the relay method for low-turnover compounds in hepatocyte
|
Wang, Xiangling
|
|
|
55 |
S |
p.
|
artikel
|
| 89 |
Evaluating the impact of glycocalyx on partitioning and distribution of basic drugs
|
Gong, Yifan
|
|
|
55 |
S |
p.
|
artikel
|
| 90 |
Evaluation of a cost-effective in vitro human model for predicting intrinsic hepatocyte clearance of slowly metabolized compounds
|
Delvaux, Nathan
|
|
|
55 |
S |
p.
|
artikel
|
| 91 |
Evaluation of a novel, primary human hepatocyte tri-culture model, truvivotm, for its ability to predict metabolic clearance of CYP, UGT, and AO substrates
|
Piekos, Stephanie
|
|
|
55 |
S |
p.
|
artikel
|
| 92 |
Evaluation of biliary excretion process of drugs and bile acids using permeation assay by a novel in vitro hepatocyte culture system (ICHEP)
|
Arakawa, Hiroshi
|
|
|
55 |
S |
p.
|
artikel
|
| 93 |
Evaluation of CYP450 activity in HLM bound to magnetizable beads
|
Chan, Tom
|
|
|
55 |
S |
p.
|
artikel
|
| 94 |
Evaluation of OSTΑ/Β transporter activity on the basal membrane of CACO-2 cell monolayers
|
Yamaguchi, Emi
|
|
|
55 |
S |
p.
|
artikel
|
| 95 |
Experiences in industry predicting hepatic clearance: Successes, disconnects, failures, and room for improvement
|
Hop, Cornelis Marcel
|
|
|
55 |
S |
p.
|
artikel
|
| 96 |
Experimental validation of the reliability of dilution method for plasma protein binding assay in human plasma using 12 commercial compounds
|
Wang, Jie
|
|
|
55 |
S |
p.
|
artikel
|
| 97 |
Exploration of bioactivation of a branched-chain ketoacid dehydrogenase kinase (BDK) inhibitor
|
Cerny, Matthew
|
|
|
55 |
S |
p.
|
artikel
|
| 98 |
Exploring the human 3D small intestinal model (epiintestinaltm) for improved prediction of oral absorption, metabolism and complex drug-drug interactions of small molecule drugs
|
Chothe, Paresh
|
|
|
55 |
S |
p.
|
artikel
|
| 99 |
Exploring the potential of machine learning approach in predicting clinical CYP3A induction-mediated drug-drug interaction
|
Sadighi, Armin
|
|
|
55 |
S |
p.
|
artikel
|
| 100 |
Exposure to mixed microplastic particles altered the fecal microbiome and its associated predictive functional pathways in mice
|
Kim, Kyle
|
|
|
55 |
S |
p.
|
artikel
|
| 101 |
For hepatically cleared drugs, liver to blood KPUU at steady-state is always equal to FH , which exposes the deficiency of the present extended clearance concept equation
|
Benet, Leslie Z.
|
|
|
55 |
S |
p.
|
artikel
|
| 102 |
From quantum mechanics to metabolism pathways
|
Oeren, Mario
|
|
|
55 |
S |
p.
|
artikel
|
| 103 |
From stratified dose adjustment to personalised dosing: Linking LCMS proteomics in tissues to more clinically practical liquid biopsy samples – Opportunities and challenges
|
Achour, Brahim
|
|
|
55 |
S |
p.
|
artikel
|
| 104 |
Functional characterization of ENT2/SLC29A2 as a uric acid transporter
|
Matake, Isamu
|
|
|
55 |
S |
p.
|
artikel
|
| 105 |
Harnessing the power of IVIVE-PBPK to explore potential discordance between local gut vs systemic bioequivalence in health and disease: the case of budesonide in crohn’s disease
|
Han, Chunyan
|
|
|
55 |
S |
p.
|
artikel
|
| 106 |
Hepatocyte CEBPA restricts the progression of liver fibrosis
|
Yan, Tingting
|
|
|
55 |
S |
p.
|
artikel
|
| 107 |
Hepatocyte formation, reactivity, and stability differences of acyl glucuronide and acyl coenzyme a conjugates
|
Heck, Carley J.S.
|
|
|
55 |
S |
p.
|
artikel
|
| 108 |
High throughput and fully automated sample preparation for quantitative bioanalysis using LC/MS/MS
|
Marahatta, Anu
|
|
|
55 |
S |
p.
|
artikel
|
| 109 |
High-throughput assessment for drug protein binding using magnetized silica beads method in human liver microsomes
|
Shao, Hongguang
|
|
|
55 |
S |
p.
|
artikel
|
| 110 |
Historical perspective - mechanisms of drug induced liver injury
|
Proctor, William
|
|
|
55 |
S |
p.
|
artikel
|
| 111 |
How much is enough? BI-907828: a MDM2-P53 antagonist with limited BBB penetration but potent efficacy in glioblastoma
|
Zhang, Wenjuan
|
|
|
55 |
S |
p.
|
artikel
|
| 112 |
Human liver chimeric mouse and trasngenic animals are useful tools for quantitatively predicting clearance and drug-drug interactions in human
|
Miyake, Taiji
|
|
|
55 |
S |
p.
|
artikel
|
| 113 |
Identification and characterisation of a novel amino acid conjugate; ergothioneine conjugate of raloxifene through in vitro and in vivo studies
|
Vachaspati, Prakash R.
|
|
|
55 |
S |
p.
|
artikel
|
| 114 |
Identification and characterization of erlotinib as a potent mechanism-based inactivator of human aldehyde oxidase
|
Dick, Ryan A.
|
|
|
55 |
S |
p.
|
artikel
|
| 115 |
Identification and characterization of novel metabolites of F2-isoprostanes
|
Nogueira, Marina
|
|
|
55 |
S |
p.
|
artikel
|
| 116 |
Identifying accurate metabolism sites of vepdegestrant using novel electron-activated dissociation high-resolution mass spectrometry
|
He, Yifei
|
|
|
55 |
S |
p.
|
artikel
|
| 117 |
Impact of donor diversity on phase I and phase II activities in cryopreserved human hepatocytes and human liver microsomes
|
Bohl, Christopher
|
|
|
55 |
S |
p.
|
artikel
|
| 118 |
Implementation of combined approaches to quantify plasma protein binding of bRo5 compounds
|
Li, Na
|
|
|
55 |
S |
p.
|
artikel
|
| 119 |
Improved PBPK model of carbamazepine as a strong CYP3A inducer
|
Lin, Jian
|
|
|
55 |
S |
p.
|
artikel
|
| 120 |
Improved predictivity of human drug oral bioavailability and first-pass metabolism utilizing human primary jejunum in a multi-organ intestinal-liver MPS system
|
Spreen, Ashley
|
|
|
55 |
S |
p.
|
artikel
|
| 121 |
Improving in vitro clearance assay performance and prediction accuracy with advanced human hepatocyte models for highly stable RO5 and BRO5 compounds
|
Kukla, David
|
|
|
55 |
S |
p.
|
artikel
|
| 122 |
Increasing the therapeutic index of ADCs with payload binding selectivity enhancers
|
Bordeau, Brandon
|
|
|
55 |
S |
p.
|
artikel
|
| 123 |
Inhibition of cytochrome P450 3A4 enzyme activity by alkaloid psilocin from magic mushrooms: potential for drug interactions
|
Wilson, Lavonne
|
|
|
55 |
S |
p.
|
artikel
|
| 124 |
In silico approach shows good predictability for free fraction in plasma and volume of distribution in human for drugs subjected to lysosomal trapping
|
Emoto, Chie
|
|
|
55 |
S |
p.
|
artikel
|
| 125 |
Integration of cyp and non-cyp hepatic abundance changes in PBPK modelling of renal impairment (RI) populations
|
Hatley, Oliver
|
|
|
55 |
S |
p.
|
artikel
|
| 126 |
Interactions of sutezolid and its active metabolite with human transporters
|
Argikar, Upendra
|
|
|
55 |
S |
p.
|
artikel
|
| 127 |
Intestine-specific induction of UDP-glucuronosyltransferases as a potential treatment approach in mitigating irinotecan-induced delayed-onset diarrhea
|
Zheng, Zicong
|
|
|
55 |
S |
p.
|
artikel
|
| 128 |
Investigating catechin-mediated effects on drug solubility as a mechanism underlying a green tea-raloxifene pharmcokinetic interaction
|
Oyanna, Victoria
|
|
|
55 |
S |
p.
|
artikel
|
| 129 |
Investigating cross-species differences of MDR1-mediated drug transport
|
Temesszentandrasi-Ambrus, Csilla
|
|
|
55 |
S |
p.
|
artikel
|
| 130 |
Investigating protein-mediated uptake drug-drug interactions using F-methotrexate as a substrate for OATP1B1 transporter
|
Parvez, Md Masud
|
|
|
55 |
S |
p.
|
artikel
|
| 131 |
Investigation of in vitro biliary excretion using the co-culture systems with fresh rat hepatocytes and rat clips-derived bile ducts
|
Onozato, Daichi
|
|
|
55 |
S |
p.
|
artikel
|
| 132 |
Investigation of the learning process of diverse compound structures by chemical language models toward toxicity prediction
|
Mizuno, Tadahaya
|
|
|
55 |
S |
p.
|
artikel
|
| 133 |
In vitro and in vivo interactions between nicotine and the cannabis terpene limonene
|
Harrelson, John
|
|
|
55 |
S |
p.
|
artikel
|
| 134 |
IN VITRO AND IN VIVO SYSTEMS FOR PREDICTING THE ADME OF PROTEIN THERAPEUTICS: ARE WE THERE YET?”
|
Rock, Brooke
|
|
|
55 |
S |
p.
|
artikel
|
| 135 |
In vitro evaluation of metabolism- and transporter-based drug interactions with sunscreen active ingredients
|
Volpe, Donna
|
|
|
55 |
S |
p.
|
artikel
|
| 136 |
In vitro evaluation of PROTAC® degrader ARV-766 for cytochrome P450- and transporter-mediated drug-drug interaction
|
Snyder, Larry
|
|
|
55 |
S |
p.
|
artikel
|
| 137 |
IN VITRO Evaluation of rat hepatic metabolic clearance using freshly isolated rat plated hepatocytes
|
Lai, Jing
|
|
|
55 |
S |
p.
|
artikel
|
| 138 |
In vitro metabolic stability and in vivo phaarmacokinetic behavior of panobinostat in mouse models for the treatment of CNS tumors
|
Zhang, Wenqiu
|
|
|
55 |
S |
p.
|
artikel
|
| 139 |
In vitro models to determine human intestinal presystemic metabolism after oral dosing
|
Lundquist, Patrik
|
|
|
55 |
S |
p.
|
artikel
|
| 140 |
In vitro uptake of an MC3 lipid nanoparticle formulation by mice, non-human primate, and human hepatocytes and Kupffer cells
|
Sandoval, Philip
|
|
|
55 |
S |
p.
|
artikel
|
| 141 |
In vivo and in vitro biotransformation of molnupiravir (MOV), An oral prodrug of the antiviral ribonucleoside analog Β-D-N4-hydroxycytidine (NHC)
|
Lu, Ping
|
|
|
55 |
S |
p.
|
artikel
|
| 142 |
Is CYP3A4 induction a good indicator for CYP2CS in cryopreserved human hepatocytes?
|
Lapham, Kimberly
|
|
|
55 |
S |
p.
|
artikel
|
| 143 |
Issues in assessing tissue: Plasma partition coefficients (KP) in PBPK models
|
Jusko, William
|
|
|
55 |
S |
p.
|
artikel
|
| 144 |
Jasmone, an essential oil component, is an antagonist of aryl hydrocarbon receptor in liver and intestinal cells
|
Vrzal, Radim
|
|
|
55 |
S |
p.
|
artikel
|
| 145 |
Keyword Index
|
|
|
|
55 |
S |
p.
|
artikel
|
| 146 |
Latest developments in nitrosamine structure-activity relationships for carcinogenicity
|
Ponting, David
|
|
|
55 |
S |
p.
|
artikel
|
| 147 |
LC-MS for identifying changes (or lack of it) in ADME across different cohorts
|
Wegler, Christine
|
|
|
55 |
S |
p.
|
artikel
|
| 148 |
Lecture title not available
|
Singh, Aman
|
|
|
55 |
S |
p.
|
artikel
|
| 149 |
Liver targeted therapy: What mist and DDI data mean for efficacy
|
Paehler, Axel
|
|
|
55 |
S |
p.
|
artikel
|
| 150 |
Lysosomal trapping measurement in multiple cell types using a high content imaging (HCI) system
|
Pacsuta, Johanna
|
|
|
55 |
S |
p.
|
artikel
|
| 151 |
Mathematical modeling of affinity design goals for CIS-binding BI-specific antibody-based molecules
|
Figueroa, Isabel
|
|
|
55 |
S |
p.
|
artikel
|
| 152 |
Mechanisms of afatinib-induced intestinal epithelial barrier dysfunction using human mini-gut model
|
Worakajit, Nichakorn
|
|
|
55 |
S |
p.
|
artikel
|
| 153 |
Mechanistic pharmacokinetics & pharmacodynamics of GaINAc-siRNA
|
Ayyar, Vivaswath
|
|
|
55 |
S |
p.
|
artikel
|
| 154 |
Mechanistic static modeling predicts low risk of unconjugated hyperbilirubinemia due to UGT1A1 inhibition by pirtobrutinib 200 mg once daily
|
Rehmel, Jessica
|
|
|
55 |
S |
p.
|
artikel
|
| 155 |
Metabolic pathways of aschantin in human liver preparations
|
Lee, Hye Suk
|
|
|
55 |
S |
p.
|
artikel
|
| 156 |
Metabolism and excretion of therapeutic peptides: current industry practices and recommendations
|
He, Minxia
|
|
|
55 |
S |
p.
|
artikel
|
| 157 |
Metabolism of DHED in vitro and in vivo to support drug optimization
|
Padilha, Elias Carvalho
|
|
|
55 |
S |
p.
|
artikel
|
| 158 |
Method development and optimization for detecting mRNAS of drug metabolizing enzymes and transporters in exosomes derived from human blood
|
Xu, Shengjie
|
|
|
55 |
S |
p.
|
artikel
|
| 159 |
Method development to correct tissue concentrations for residual blood: Application to drug distribution in brain tumors
|
Oh, Ju-Hee
|
|
|
55 |
S |
p.
|
artikel
|
| 160 |
Microbiome impacts on drug metabolism
|
Goodman, Andrew
|
|
|
55 |
S |
p.
|
artikel
|
| 161 |
Modern pediatric drug development: Practical case examples and regulatory outcomes from novel applications of modelling
|
Gertz, Michael
|
|
|
55 |
S |
p.
|
artikel
|
| 162 |
Monocarboxylate transporter 10: substrate-dependent mode of transport
|
Rodriguez, Acilegna
|
|
|
55 |
S |
p.
|
artikel
|
| 163 |
Multisite evaluation of nonclinical biodistribution study in cell therapy products
|
Kamiyama, Yoshiteru
|
|
|
55 |
S |
p.
|
artikel
|
| 164 |
N-nitrosamine safety assessments - Current challenges
|
Dobo, Krista
|
|
|
55 |
S |
p.
|
artikel
|
| 165 |
Novel approaches and troubleshooting for developing a high-throughput oligonucleotide LC-MS method beyond the current stage
|
Yun, Changhong
|
|
|
55 |
S |
p.
|
artikel
|
| 166 |
Novel approach to determine plasma protein binding for labile compounds using equilibrium dialysis
|
Chao, Piyun
|
|
|
55 |
S |
p.
|
artikel
|
| 167 |
Novel coc-based liver tissue chip for predictive pharmacokinetic and toxicology applications
|
Rajan, Shiny
|
|
|
55 |
S |
p.
|
artikel
|
| 168 |
Novel metabolomics approach to identify biomarkers of organic anion renal transporters
|
Thakur, Aarzoo
|
|
|
55 |
S |
p.
|
artikel
|
| 169 |
Novel multi-tissue chips for predictive pharmacokinetic studies
|
Sherfey, Jason
|
|
|
55 |
S |
p.
|
artikel
|
| 170 |
OATP1B-mediated hepatic uptake of low-molecular weight acid compounds: assessment of HIF prolyl-hydroxylase inhibitors (DUSTATS)
|
Bi, Yi-An
|
|
|
55 |
S |
p.
|
artikel
|
| 171 |
OCT1 transporter kinetics and long-term modulation studies in 3D cultured primary human hepatocytes
|
Karlgren, Maria
|
|
|
55 |
S |
p.
|
artikel
|
| 172 |
One size does not fit all: Preclinical tools to characterize the pharmacokinetics and biodistribution of GaINAc-siRNA
|
Lade, Julie
|
|
|
55 |
S |
p.
|
artikel
|
| 173 |
Opportunities and challenges in drug development for retinal diseases
|
Jakubiak, Paulina
|
|
|
55 |
S |
p.
|
artikel
|
| 174 |
Optimization of methods for reducing turnaround time and compound consumptionwith echo liquid handling and automation enabling high capacity analysis for ADME screening
|
Roychowdhury, Shantanu
|
|
|
55 |
S |
p.
|
artikel
|
| 175 |
P-GP limits rodent oral absoprtion of protacs
|
Steyn, Stefanus
|
|
|
55 |
S |
p.
|
artikel
|
| 176 |
Pharmacokinetic feasibilities of co-amorphous dispersions of mirabegron in rats and mice
|
Choi, Young Hee
|
|
|
55 |
S |
p.
|
artikel
|
| 177 |
Pharmacokinetic interaction of caffeine and theophylline in mice
|
Choi, Young Hee
|
|
|
55 |
S |
p.
|
artikel
|
| 178 |
Pharmacokinetic properties of a truncated milk fat globule-EGF-like factor 8 in rats
|
Kim, Byoung Soo
|
|
|
55 |
S |
p.
|
artikel
|
| 179 |
Pharmacokinetics and pharmacodynamics of endogenous and exogenous cortisol in premenopausal, healthy women
|
Authement, Aurora
|
|
|
55 |
S |
p.
|
artikel
|
| 180 |
Pharmacokinetics of ginsenosides and effect of the lactic acid bacteria on pharmacokinetics of ginsenosides in mice and human
|
Jeon, Ji-Hyeon
|
|
|
55 |
S |
p.
|
artikel
|
| 181 |
Pharmacokinetics of perfluoroocanoic acid and perfluorohexane sulfonic acid in various rat models
|
Moon, Kyungsun
|
|
|
55 |
S |
p.
|
artikel
|
| 182 |
Pharmacokinetic study of rosiglitazone in animal model of obesity
|
Moon, Kyung-Sun
|
|
|
55 |
S |
p.
|
artikel
|
| 183 |
Pharmacology and translational aspects
|
Trame, Mirjam
|
|
|
55 |
S |
p.
|
artikel
|
| 184 |
Physiologically based pharmacokinetic model for miltefosine in mice
|
Ramisetty, Bhargavi Srija
|
|
|
55 |
S |
p.
|
artikel
|
| 185 |
Physiologically based pharmacokinetic modeling of adeno-associated viruses and the transgene product
|
Liu, Shufang
|
|
|
55 |
S |
p.
|
artikel
|
| 186 |
Plasma protein binding in special populations: do current PBPK models correctly account for potential changes to fraction unbound?
|
Al-Qassabi, Jokha
|
|
|
55 |
S |
p.
|
artikel
|
| 187 |
Plasma protein binding of oligonucleotides using rapid agarose gel electrophoretic mobility shift assay
|
Wang, Jie
|
|
|
55 |
S |
p.
|
artikel
|
| 188 |
Pleiotropic effects of rifampicin as a mixed-mode perpetrator drug assessed simultaneously using multiple endogenous biomarkers in dogs
|
Liu, Renmeng
|
|
|
55 |
S |
p.
|
artikel
|
| 189 |
Poster Details
|
|
|
|
55 |
S |
p.
|
artikel
|
| 190 |
Potential ADME-related issues for PROTACs
|
Hoffman, Matthew
|
|
|
55 |
S |
p.
|
artikel
|
| 191 |
Practical use of mechanistic modeling to discern real word complex drug interactions
|
Grillo, Joseph
|
|
|
55 |
S |
p.
|
artikel
|
| 192 |
Preclinical evaluation of the potential for cytochrome P450 inhibition and induction by tucatinib
|
Sun, Hao
|
|
|
55 |
S |
p.
|
artikel
|
| 193 |
Prediction and validation of fetal exposure to dual BCRP/P-GP drug substrates using the proteomics informed efflux ratio-relative expression factor (ER-REF) approach and PBPK modeling and simulation
|
Balhara, Ankit
|
|
|
55 |
S |
p.
|
artikel
|
| 194 |
Prediction and validation of human hepatobiliary clearances and hepatic concentrations of transported drugs using the relative expression factor (REF) and PET imaging approaches
|
Yin, Mengyue (Melody)
|
|
|
55 |
S |
p.
|
artikel
|
| 195 |
Prediction of drug-drug interaction of ensitrelvir as CYP3A substrate using physiologically-based pharmacokinetic model
|
Horiuchi, Kana
|
|
|
55 |
S |
p.
|
artikel
|
| 196 |
Prediction of human clearance using human liver microsomes and hepatocytes with 455 drugs
|
Tess, David
|
|
|
55 |
S |
p.
|
artikel
|
| 197 |
Prediction of pharmacokinetics and pharmacodynamics in human for IRAK4 targeted protein degrader
|
Chen, Dapeng
|
|
|
55 |
S |
p.
|
artikel
|
| 198 |
Prevention of irinotecan-induced intestinal toxicity by locally bioavailable herbal components via maintaining gut oxidative stress homeostasis
|
Saponjac, Vesna Tumbas
|
|
|
55 |
S |
p.
|
artikel
|
| 199 |
Projections for future challenges and opportunities for pharmacokineticists
|
Balthasar, Joseph
|
|
|
55 |
S |
p.
|
artikel
|
| 200 |
Promiscuity and quantitative contribution of UGT2B17 in drug and steroid metabolism determined by experimental and computational approaches
|
Ahire, Deepak
|
|
|
55 |
S |
p.
|
artikel
|
| 201 |
Protein-bound uremic toxin clearance as biomarkers of kidney tubular function in diabetic kidney disease
|
Ahmed, Sabbir
|
|
|
55 |
S |
p.
|
artikel
|
| 202 |
Quantitative estimation of fraction metabolized via CYP3A for low turnover compounds, using hepatocyte co-culture system
|
Karataeva, Natalia
|
|
|
55 |
S |
p.
|
artikel
|
| 203 |
Quantitative proteomics identifies significant changes in the abundance and composition of hepatic drug metabolizing enzymes in heavy alcohol drinkers
|
Gaither, Kari
|
|
|
55 |
S |
p.
|
artikel
|
| 204 |
Radiolabeled absorption, distribution, metabolism and excretion studies in preclinical animals
|
Zhou, Ying
|
|
|
55 |
S |
p.
|
artikel
|
| 205 |
Recapitulation of native human expression patterns of key transport and drug metabolism genes in an in vitro human donor-derived intestinal epithelium
|
Bliton, Jarrett
|
|
|
55 |
S |
p.
|
artikel
|
| 206 |
Recent studies on metabolism, DNA adducts, and biomarkers of tobacco carcinogens
|
Hecht, Stephen
|
|
|
55 |
S |
p.
|
artikel
|
| 207 |
Redox metabolism in intestine and liver aggravates retronecine-type pyrrolizidine alkaloids-induced liver injury
|
Lin, Ge
|
|
|
55 |
S |
p.
|
artikel
|
| 208 |
Relative expression versus activity factor (ref vs. raf) to estimate fractional contribution of individual UGT isoforms (FGLUC) in drug glucuronidation
|
Subash, Sandhya
|
|
|
55 |
S |
p.
|
artikel
|
| 209 |
Rifampin- and silymarin-mediated pharmcokinetic interactions of pitavastatin, pravastatin, coproporphyrin I, and coproporphyrin III in a transgenic OATP1B mouse model
|
Bechtold, Baron
|
|
|
55 |
S |
p.
|
artikel
|
| 210 |
Risk of pharmacokinetic drug-drug interactions with novel drugs approved by the US FDA in 2022: a detailed review of DDI data from NDA documentation
|
Yu, Jingjing
|
|
|
55 |
S |
p.
|
artikel
|
| 211 |
Roles of human cytochrome P450 1A2, 2C9, and 3A4/5 enzymes in drug oxidations mediated by metabolically inactivated human hepatocytes in previously transplanted chimeric mice
|
Yamazaki, Hiroshi
|
|
|
55 |
S |
p.
|
artikel
|
| 212 |
Smart compound library based on machine learning, sensing technology, and programmable logic control
|
Li, Hongye
|
|
|
55 |
S |
p.
|
artikel
|
| 213 |
Spatial mapping of gemcitabine and its pharmacologically active metabolites in tissues using MALDI mass spectrometry imaging
|
Phulara, Nav Raj
|
|
|
55 |
S |
p.
|
artikel
|
| 214 |
Stereoisomer separation of drugs and biomarkers using supercritical fluid chromatography to support PK/PD studies
|
Li, Fangbiao
|
|
|
55 |
S |
p.
|
artikel
|
| 215 |
Story of maturation - Modelers vs models in the paediatric space
|
Rostami-Hodjegan, Amin
|
|
|
55 |
S |
p.
|
artikel
|
| 216 |
Strategies for DDI risk assessment between novel oncology agents and combination generic standard of care (SOC) agents
|
Visswanathan, Ravi
|
|
|
55 |
S |
p.
|
artikel
|
| 217 |
Strategies for de-risking n-nitrosamine impurities in APIS
|
Bercu, Joel
|
|
|
55 |
S |
p.
|
artikel
|
| 218 |
Strategies for enhancing oral exposure of water-insoluble compounds
|
Chen, Yu
|
|
|
55 |
S |
p.
|
artikel
|
| 219 |
Substrate-dependent characteristics in the transport function of SLC19A3: examination of the aspect of its sensitivity to flavonoids
|
Yuasa, Hiroaki
|
|
|
55 |
S |
p.
|
artikel
|
| 220 |
Successful optimization of pharmacokinetics and pharmacodynamics of oral cyclic peptide PCSK9 inhibitors
|
Bueters, Tjerk JH.
|
|
|
55 |
S |
p.
|
artikel
|
| 221 |
Suppression and induction of UGT by rhein and alvocidib in intestinal epithelial cells
|
Du, Ting
|
|
|
55 |
S |
p.
|
artikel
|
| 222 |
Synthesis and characterization of human metabolites of the echinocandid drug rezafungin by microbial biotransformation
|
Shanu-Wilson, Julia
|
|
|
55 |
S |
p.
|
artikel
|
| 223 |
Systematic investigation of the metabolism of cannabinoids by human cytochrome p450s
|
Das, Aditi
|
|
|
55 |
S |
p.
|
artikel
|
| 224 |
Tenofovir activation is diminished in the brain and liver of creatine kinase brain-type knockout mice
|
Eberhard, Colten
|
|
|
55 |
S |
p.
|
artikel
|
| 225 |
The changing landscape for hame: practical experience from a data analysis of 500 studies
|
Favara, Sarah
|
|
|
55 |
S |
p.
|
artikel
|
| 226 |
The characterization of the pharmacokinetic profile of anti-tumor B (ATB) in oral cancer patients
|
Chen, Jie
|
|
|
55 |
S |
p.
|
artikel
|
| 227 |
The distribution of perfluorooctanesulfonate (PFOS) into the liver is not dependent on fatty acid binding protein (FABP)
|
Modaresi, Sadegh
|
|
|
55 |
S |
p.
|
artikel
|
| 228 |
The effect of clofazimine in modulating intracellular concentrations of remdesivir and GS-441524: A potential mechanism of enhancing antiviral effects against SARS-COV-2
|
Jony, Md Rasheduzzaman
|
|
|
55 |
S |
p.
|
artikel
|
| 229 |
The effect of traditional herbal medicine on the permeability of clarithromycin and loxoprofen in CACO-2 cell model
|
Shin, Sabin
|
|
|
55 |
S |
p.
|
artikel
|
| 230 |
The inhibitory effects of major cannabinoids and their metabolites on R- and S-oxazepam metabolism
|
Bardhi, Keti
|
|
|
55 |
S |
p.
|
artikel
|
| 231 |
The mass balance recovery, absorption, metabolism, and excretion of [14C]-orvepitant in healthy male subjects after oral dosing: clinical conduct & mass balance
|
Shaw, Iain
|
|
|
55 |
S |
p.
|
artikel
|
| 232 |
The mass balance, recovery, absorption, metabolism, and excretion of [14C]-orvepitant in healthy male subjects after oral dosing: metabolite characterisation
|
Colato, Dimitri
|
|
|
55 |
S |
p.
|
artikel
|
| 233 |
The mass balance recovery, absorption, metabolism, and excretion of [14C]-orvepitant in healthy male subjects after oral dosing: radiosynthesis of [14c]-orvepitant
|
Carver, David
|
|
|
55 |
S |
p.
|
artikel
|
| 234 |
The practical impact of the FDA draft guidance on human mass balance studies – a year of client discussions
|
Shaw, Iain
|
|
|
55 |
S |
p.
|
artikel
|
| 235 |
The spectrum of hepatic clearance models, from old to new
|
Pang, K. Sandy
|
|
|
55 |
S |
p.
|
artikel
|
| 236 |
This is no longer just about liver: LC-MS proteomics for organ exposure brain/kidney/gut/skin/placenta
|
Al-Majdoub, Zubida
|
|
|
55 |
S |
p.
|
artikel
|
| 237 |
Title page
|
|
|
|
55 |
S |
p.
|
artikel
|
| 238 |
TOC
|
|
|
|
55 |
S |
p.
|
artikel
|
| 239 |
Toxicity of trimethoprim and sulfamethoxazole
|
Goldman, Jennifer
|
|
|
55 |
S |
p.
|
artikel
|
| 240 |
Translational PK/PD of the targeted radioligand therapy pluvicto
|
Silvia, Larissa Lachi
|
|
|
55 |
S |
p.
|
artikel
|
| 241 |
Transporter activity characterization in a novel human hepatic cell-based tri-culture system
|
Mitra, Pallabi
|
|
|
55 |
S |
p.
|
artikel
|
| 242 |
Transporter or membrane barriers effects on hepatic clearance (the extended clearance equation) models and the need for scaling for IVIVE
|
Sugiyama, Yuichi
|
|
|
55 |
S |
p.
|
artikel
|
| 243 |
UGT-mediated clearance IVIVE may be improved using relative activity factor approach
|
Shaikh, Sahil
|
|
|
55 |
S |
p.
|
artikel
|
| 244 |
Understanding CYP3A4 and P-GP mediated drug-drug interactions through PBPK modeling - case example of pralsetinib
|
Bowman, Christine
|
|
|
55 |
S |
p.
|
artikel
|
| 245 |
Understanding the role of CYP3A in the metabolism of kinase inhibitors marketed in the past decade to better manage the risk of clinical drug-drug interactions
|
Yu, Jingjing
|
|
|
55 |
S |
p.
|
artikel
|
| 246 |
Unveiling the intracellular journey: GOLGA8N-mediated subcellular trafficking of siRNA drugs and its implications on silencing efficacy
|
Tawfik, Sherouk
|
|
|
55 |
S |
p.
|
artikel
|
| 247 |
Use of a renal OCT2/Mate biomarker (N1-methylnicotinamide) to enable the early clinical assessment of metformin drug interaction potential
|
Mathialagan, Sumathy
|
|
|
55 |
S |
p.
|
artikel
|
| 248 |
Use of human liver microsomes to assess flavin-containing monooxygenase (FMO) metabolism in vitro
|
Delvaux, Nathan
|
|
|
55 |
S |
p.
|
artikel
|
| 249 |
Use of mathematical modeling to guide out-of-the-box thinking for ADC development
|
Thurber, Greg
|
|
|
55 |
S |
p.
|
artikel
|
| 250 |
Using quantitative systems pharmacology (QSP) models to characterize the PK of novel drug modalities
|
Nobisch, Jamie
|
|
|
55 |
S |
p.
|
artikel
|
| 251 |
Utility of common in vitro systems for predicting circulating metabolites
|
Freiberger, Elyse
|
|
|
55 |
S |
p.
|
artikel
|
| 252 |
Utilization of target engagement in tissues measured by immunoaffinity LC-MS/MS for PBPK modeling of monoclonal antibody
|
Hoshi, Yutaro
|
|
|
55 |
S |
p.
|
artikel
|
| 253 |
Utilizing various plasma protein binding tools for free fraction determination of lipophilic and lipopeptide drugs
|
Johnson, Kevin
|
|
|
55 |
S |
p.
|
artikel
|
| 254 |
Validation of a modified in situ perfusion model for measuring drug intestinal excretion and evaluation of the drug-drug interactions in the intestine by I.V. administration
|
Sun, Rongjin
|
|
|
55 |
S |
p.
|
artikel
|
| 255 |
Validation of LC-MS/MS method for the quantification of buprenorphine and its metabolites in rat’s blood, oral fluid, salivary gland and application the assay on pharmacokinetic study
|
Zheng, Zicong
|
|
|
55 |
S |
p.
|
artikel
|
| 256 |
Verification of a physiologically based pharmacokinetic model of caffeine that incorporates mechanistic descriptors of absorption
|
Rehmel, Jessica
|
|
|
55 |
S |
p.
|
artikel
|
| 257 |
What is new in LC-MS proteomics: Techniques and applications in IVIVE and precision medicine
|
Prasad, Bhagwat
|
|
|
55 |
S |
p.
|
artikel
|
| 258 |
What is the role of CYP1A1 in drug metabolism?
|
Di, Li
|
|
|
55 |
S |
p.
|
artikel
|
Tijdschrift beschrijving